SHORT COMMUNICATION
Pharmacological treatment of recurrent idiopathic anterior uveitis
Online publication date: 2011-12-28
Reumatologia 2011;49(6):397-403
KEYWORDS
anterior uveitisrecurrent anterior uveitisidiopathic anterior uveitisdisease modifying anti-rheumatic drugs
ABSTRACT
Recurrent anterior uveitis (AU) is an autoimmune disease that in 20% of patients leads to severe visual loss or blindness, thereby a severe disability and significant quality of life impairment. That is why, it is important to conduct a long term treatment after an acute phase of the disease, to keep the remission as long as possible. Up to 50% of patients with recurrent AU have no additional symptoms of systemic disease. This situation, classified as idiopathic AU (IAU), causes a lot of problems when a therapeutic strategy has to be chosen. Nevertheless, IAU is considered to be a first symptom of spondylarthropathy (SpA), even several dozen years prior to other typical manifestations of SpA. There have been published few papers concerning only small groups of patients with IAU, treated with disease modifying anti-rheumatic drugs. The authors present the recommendations for systemic treatment of IAU, based on their own clinical experience and systematic review of the literature.
REFERENCES (43)
1.
Munoz-Fernandez S, Martin-Mola E: Uveitis. Best Pract Clin Rheumatol 2006, 20, 487-505. .
2.
Kański JJ, Turno-Kręcicka A: Zapalenie błony naczyniowej oka. Elsevier Urban & Partner 1999, wyd 1. .
3.
Pato E, Banares A, Jover JA, Fernandez-Gutierrez B, Godoy F, Morado C, Mendez R, Hernandez-Garcia C: Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000, 27, 2198-2202. .
4.
Szechiński J, Wiland P, Wiland G: Reumatologia. Zmiany narządowe. Górnicki Wyd Med 2001, wyd 1, pp. 237-270. .
5.
Chung YM, Liao HT, Lin KC, Lin YC, Chou CT, Chen CH, Tsai CP: Prevalence of spondyloarthritis in 504 Chinese patients with HLA-B27 associated acute anterior uveitis. Scand J Rheumatol 2008, 25, 1-7. .
6.
Bachta A, Tłustochowicz M: Czy idiopatyczne zapalenie tęczówki jest chorobą reumatyczną – obserwacje własne. Reumatologia 2006, 44(6), 304-308. .
7.
Martin TM, Smith JR, Rosenbaum JT: Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Op Rheum 2002, 14, 337-341. .
8.
Pivetti-Pezzi P, Accorinti M, La Cava M, Colabelli Gisoldi RA, Abdulaziz MA: Endogenous uveitis: an analysis of 1,417 cases. Ophtalmologica 1996, 210, 234-238. .
9.
Schumacher HR, Bardin T: The spondyloarthropathies. Classification and diagnosis. Do we need new terminologies. Bailleres Clin Rheumatol 1998, 12, 551-565. .
10.
Zeboulon N, Dougados M, Gossec L: Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008, 67, 955-959. .
11.
Anglade E, Whitcup SM: The diagnosis and management of uveitis. Drugs 1995, 49, 213-223. .
12.
Smith JR, Rosenbaum JT: Management of uveitis. A rheumatologic perspective. Arthritis Rheum 2002, 46, 309-318. .
13.
Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I: Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983, 2, 235-238. .
14.
Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB: Randomized double-masked study of cyclosporine compared to prednisone in the treatment of endogenous uveitis. Am J Ophthalmol 1991, 112, 138-146. .
15.
Vitale AT, Rodriguez A, Foster CS: Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996, 103, 365-373. 16. Trzcińska-Dąbrowska Z: Cyclosporine in the treatment of uveitis. Klin Oczna 1992, 94, 133-134. .
16.
BenEzra D, Cohen E, Rakotomalala M et al.: Treatment of endogenous uveitis with cyclosporine A. Transplant Proc 1988, 20, 122-127. .
17.
Secchi AG, De Rosa C, Pivetti-Pezzi P et al.: Open noncontrolled multicenter long-term trial with cyclosporin with endogenous non-infectious uveitis. Ophtalmologica 1991, 202, 217-224. .
18.
Pascalis L, Pia G, Aresu G et al.: Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun 1993, 6, 467-480. .
19.
Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Volcker HE: Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmology 1992, 1, 142-144. .
20.
Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992, 99, 1419-1423. .
21.
Kaplan-Messas A, Barkana Y, Avni I, Neumann R: Methotrexate as a first line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003, 11, 131-139. .
22.
Kiss S, Letko E, Qamruddin S, Baltatzis S, Foster CS: Long-term progression, prognosis and treatment of patients with recurrent ocular manifestations of Reiter’s syndrome. Ophthalmology 2003, 110, 1764-1769. .
23.
Bom S. Zamir P, Lightman S: Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 2001, 9, 35-40. .
24.
Samson CM, Waheed N, Baltatzis S, Foster CS: Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001, 108, 1134-1139. .
25.
Munoz-Fernandez S, Garcia-Aparicio AM, Hidalgo MV, Platero M, Schlincker A, Bascones ML, Pombo M, Morente P, Sanpedro J, Martin-Mola E: Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye AOPM, 8 Aug 2008, 198. .
26.
Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Ban~ares A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye. 2000 Jun, 14, 340-343. .
27.
Chen J, Liu C: Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006 Apr, 33(4), 722-731. .
28.
Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV: Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 2008, 16, 161-165. .
29.
Andrasch RH, Pirofsky B, Burns RP: Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978, 96, 247-251. .
30.
Durrani K, Papaliodis GN, Foster CS: Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004, 111, 960-965. .
31.
Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP: Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005, 112, 1472-1477. .
32.
El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophtalmology 2002, 109, 2342-2346. .
33.
El-Shabrawi Y, Mangge H, Hermann J: Anti-tumor necrosis factor treatment in chronic recurrent inflammation of the anterior segment of the eve in patients resistant to standard immunomodulatory treatment. Ann Rheum Dis 2003, 62, 1243-1244. .
34.
Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52, 2447-2451. .
35.
Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, Freundlich B: Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010 Jan, 69(1), 226-229. .
36.
Rudwaleit M, Ro/devand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009 May, .
38.
Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56, 3248-3252. .
39.
Cobo-Ibanez T, del Carmen-Ordonez M, Munoz-Fernandez S, Maredo-Prado R, Martin-Mola E: Do TNF-βlockers reduce or induce uveitis? Rheumatology 2008, 47, 731-741. .
40.
Lim LL, Suhler EB, Smith JR: Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol 2006, 34, 365-374. .
41.
Yeh S, Faia LJ, Nussenblatt RB: Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol 2008, 30, 145-164. .
42.
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophtalmol 2000, 130, 492-513. .
43.
Rothova A, Suttorp-van Schulten MSA, Treffers WF, Kijlstra A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophtalmology 1996, 80, 332-336.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
